RVPH (Reviva Pharmaceuticals Holdings Inc.) רווח למניה בשנים עשר החודשים האחרונים

Reviva Pharmaceuticals (RVPH) is developing its neurobiological business by implementing eco-friendly packaging and energy-saving standards. The current EPS YoY TTM trend on the GURU.Markets chart shows that the parameter value is 62.30. This is supported by the creation of the Brilaroxazin closed ecosystem to improve patient retention and the deployment of software robots that accelerate clinical data analysis to expedite time-to-market for its drugs.
Reviva Pharmaceuticals - פילוחים אנליטיים ומדדי מפתח (RVPH)

The TTM earnings per share trend reflects the business's actual resilience to external shocks, smoothing out one-time revenue spikes to assess fundamental strength. Given the maximum dependence of Reviva Pharmaceuticals (RVPH) on external CROs and CMOs, the year-over-year TTM EPS history helps identify hidden overpayment risks arising from the high cost of outsourcing clinical tracking.